Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, tofacitinib and baricitinib showed comparable efficacy and tolerability under unorthodox weight-stratified dosing in pediatric patients with moderate-to-severe alopecia areata over 24 weeks; however, the unorthodox baricitinib regimen yielded a lower effectiveness in severe cases, emphasizing the importance of adherence to guideline-recommended dosing.

This study found that tofacitinib and baricitinib, when administered with unorthodox weight-stratified dosing in pediatric patients with moderate-to-severe AA, showed comparable efficacy and tolerability, though baricitinib's efficacy decreased with non-standard dosing.

The review concluded that better studies are needed to prove if Low-Level Laser Therapy devices for hair growth really work.

This ruling by the UK Court of Appeal allows patents for pharmaceuticals based on new dosing regimens and can override previous decisions to align with European Patent Office practices.

This study on alopecia areata meta-analyses highlights the risk of misleading results when ineffective, unsafe, or unapproved dosing regimens are included, recommending methodological safeguards to ensure accurate data interpretation and avoid inappropriate causal inferences.

This review discusses the pharmacologic properties, mechanisms, dosing options, and adverse effects of systemic glucocorticosteroids in dermatology, but reports no new findings.

The trial helped find the best dose of deuruxolitinib for treating alopecia areata.

In this study of patients with androgenetic alopecia taking off-label low-dose oral minoxidil, adverse events like dizziness/lightheadedness, hypertrichosis, and extremity edema were observed in 14.9% of patients, with females experiencing more adverse events; higher doses increased dizziness risk, leading researchers to recommend cautious dosing approaches.

Finasteride 1 mg every other month effectively maintains hair growth in androgenic alopecia.

This article discusses the importance of optimizing treatment protocols for chemotherapy-induced alopecia and reports no new clinical results; the authors emphasize improving patient outcomes and quality of life.

This study found that an adjusted dosing regimen of oral betamethasone led to complete hair regrowth in an 8-year-old with alopecia totalis, without observed side effects.

This review discusses the FDA-approved JAK inhibitor baricitinib as a treatment for alopecia areata, highlighting its dosing regimen, clinical challenges, and the need for additional safety data while exploring the potential of other topical and sublingual JAK inhibitors under investigation.

This study reviewed evidence suggesting that systemic corticosteroids, particularly in pulse regimens like dexamethasone and betamethasone oral mini-pulse, effectively slow vitiligo progression and support repigmentation, while offering a favorable safety profile compared to continuous therapy.

In this study, twice-weekly and thrice-weekly dutasteride improved hair growth and were well-tolerated, although thrice-weekly dosing did not significantly outperform finasteride 1 mg daily for increasing hair count.

This article states that hormone therapy with estrogens and antiandrogens for transgender females is within an obstetrician-gynecologist's practice scope and involves careful dosing and monitoring to manage short-term thrombotic risks.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

In this study, a high daily dose of interferon alfa-2b administered initially six times a week for two weeks followed by thrice weekly for 12 weeks was most effective in sustaining normal ALT values in patients.

Oral minoxidil effectively controls blood pressure quickly and safely.

This article reviews the treatment options for tinea capitis, suggesting that itraconazole, terbinafine, and fluconazole are effective and safe alternatives to griseofulvin but reports no new clinical results.

This abstract highlights the potential applications of exosomes in dermatology, including scar treatment and hair regeneration, but notes that further clinical studies are needed to confirm their safety and efficacy and address regulatory challenges.

This study found that isotretinoin therapy for acne vulgaris typically causes mild mucocutaneous adverse events, which are reversible and vary individually.

This research discusses the parallel clinical development of ritlecitinib, an oral Janus kinase 3/tyrosine kinase inhibitor, for treating conditions such as alopecia areata, vitiligo, ulcerative colitis, Crohn's disease, and rheumatoid arthritis. Results are not reported in the abstract.

The FDA approved a new Pfizer drug for hair loss in teens.

This review highlights Ritlecitinib as a promising new oral treatment for Alopecia Areata, emphasizing its targeted action and potential efficacy, especially in adults and adolescents, though it notes the need for further real-world effectiveness and long-term safety studies.

Low dose valproic acid treatment caused hair loss in a young patient.

The trial is ongoing, but researchers are evaluating the efficacy and safety of REZPEG, a potential new therapy for severe alopecia areata, which selectively expands regulatory T cells.

In this systematic review, significant improvements in clinical severity, patient-reported outcomes, and quality of life were reported for dupilumab compared to placebo in patients with moderate-to-severe atopic dermatitis, prurigo nodularis, and alopecia areata, supporting its efficacy and safety for these dermatological conditions.

This case report describes a 3-month-old infant with acquired acrodermatitis enteropathica who was successfully treated with zinc supplementation over 3 weeks.

The authors concluded that capecitabine and high-dose toremifene may be an effective treatment option for patients unable to undergo anthracycline or taxane therapies, based on one woman's cancer management.

This article reviews the epidemiology, presentation, and treatment of tinea infections and offers no new clinical findings, advocating for the use of oral antifungals and proper hygiene practices.